As of November 6, 2026, MoonLake Immunotherapeutics is a publicly traded company (Nasdaq: MLTX). The largest holder reporting an active stake on Schedule 13D is Biotechnology Value Fund LP, at 19.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Deep Track Capital (9.74%), T. Rowe Price (5.3%) (Schedule 13D/A, June 29, 2026).
Is this your company?
About to sign with, pay or invest in MoonLake Immunotherapeutics? See the free Snapshot first.
Free to see. No signup.
Is MoonLake Immunotherapeutics a real, registered company?
- MoonLake Immunotherapeutics files with the SEC under CIK 1821586 (its SEC filings).
- Its shares are listed under the ticker MLTX on Nasdaq (SEC company record).
- Incorporated in E9; business address in Zug, V8, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MOONLAKE IMMUNOTHERAPEUTICS in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-08-14).
Who are MoonLake Immunotherapeutics' owners and officers?
MoonLake Immunotherapeutics: business address in Zug, V8; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | T. Rowe Price Investment Management, Inc. | 5.3% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 9.74% |
| Schedule 13G/A, 2026-08-14 | Cormorant Asset Management, LP | 4.35% |
| Schedule 13D/A, 2026-06-29 | Biotechnology Value Fund L P | 19.7% |
| Schedule 13G/A, 2026-05-15 | Cormorant Asset Management, LP | 6.25% |
| Schedule 13D/A, 2026-04-02 | Biotechnology Value Fund L P | 22.3% |
| Schedule 13G, 2026-02-17 | Cormorant Asset Management, LP | 6.1% |
| Schedule 13G/A, 2025-11-14 | Avoro Capital Advisors LLC | 3.15% |
| Schedule 13G, 2025-11-12 | Deep Track Capital, LP | 6.46% |
| Schedule 13D/A, 2025-11-10 | Biotechnology Value Fund L P | 27.7% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 1.1% |
| Schedule 13G/A, 2025-10-01 | Chen Bihua | 3.14% |
Questions about who owns MoonLake Immunotherapeutics
Who owns MoonLake Immunotherapeutics?
On this page, 3 holders' latest ownership filings report 5% or more of MoonLake Immunotherapeutics: Biotechnology Value Fund L P (19.7%, Schedule 13D/A, filed 2026-06-29), Deep Track Capital, LP (9.74%, Schedule 13G/A, filed 2026-08-14) and T. Rowe Price Investment Management, Inc. (5.3%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of MoonLake Immunotherapeutics?
By the share each holder's latest filing reports, the largest holders of MoonLake Immunotherapeutics on this page are Biotechnology Value Fund L P (19.7%), Deep Track Capital, LP (9.74%) and T. Rowe Price Investment Management, Inc. (5.3%).
When did Biotechnology Value Fund L P buy into MoonLake Immunotherapeutics?
The filings give report dates, not purchase dates. The earliest filing from Biotechnology Value Fund L P on this page is the Schedule 13D/A, filed 2025-11-10, reporting 27.7%; its latest, Schedule 13D/A filed 2026-06-29, reports 19.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on MoonLake Immunotherapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MoonLake Immunotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MoonLake Immunotherapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own MoonLake Immunotherapeutics shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 2,774,893 shares (3.3% of shares outstanding) (Form 4, 2026-07-13).
- , the chief scientific officer: 2,746,587 shares (3.2% of shares outstanding), 35,389 held directly and 2,711,198 indirectly (Form 4, 2026-07-29).
- Cormorant Global Healthcare Master Fund, LP: 1,994,173 shares (2.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-01).
- Cormorant Asset Management, LP: 1,994,173 shares (2.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-01).
- Cormorant Private Healthcare Fund II, LP: 1,994,173 shares (2.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-01).
Shares outstanding: 85,106,685 as of 2026-11-01, from the company's latest SEC cover page.
How much has MoonLake Immunotherapeutics raised?
No fundraising or offering filing from MoonLake Immunotherapeutics is on file with us.
Keep reading
More on MoonLake Immunotherapeutics and the records around it.
MoonLake Immunotherapeutics elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Chen Bihua also filed stake reports on 1 other company: BridgeBio Oncology Therapeutics, Inc. (Jul 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/moonlake-immunotherapeutics